Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses-Reference-Cited by-同舟云学术

Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses

Published:2016-06-02 Issue:51 Volume:7 Page:83987-84002
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Broséus Julien¹²,Chen Gaili³,Hergalant Sébastien¹,Ramstein Gérard⁴,Mounier Nicolas⁵,Guéant Jean-Louis¹⁶,Feugier Pierre¹⁷,Gisselbrecht Christian⁸,Thieblemont Catherine⁸⁹,Houlgatte Rémi¹¹⁰

Affiliation:

1. Inserm U954, Faculty of Medicine, Nancy, France

2. Hematology, Laboratory Department, University Hospital of Nancy, Nancy, France

3. ZhongNan Hospital of Wuhan University, Wuhan, China

4. LINA DUKe, UMR 6241, Université de Nantes, Nantes, France

5. Hemato-oncology, University Hospital of l’Archet, Nice, France

6. Biochemistry, Laboratory Department, University Hospital of Nancy, Nancy, France

7. Hematology Department, University Hospital of Nancy, Nancy, France

8. APHP, Saint-Louis Hospital, Hemato-Oncology Department, Paris, France

9. Paris Diderot University-Sorbonne Paris-Cité, Paris, France

10. DRCI, University Hospital of Nancy, Nancy, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group;Cancer Genetics;2022-11

2. Prognostic models for early and late tumor progression prediction in nasopharyngeal carcinoma: An analysis of 8292 endemic cases;Cancer Medicine;2022-10-27

3. Mutation profile of diffuse large B-cell lymphoma with relapses in the central nervous system;Advances in Molecular Oncology;2022-10-07

4. The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review;Journal of Developmental Biology;2022-07-27

5. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL;Leukemia & Lymphoma;2022-05-03